IRIS ZEMZOUM – PRESIDENT, NOVARTIS ASIA PACIFIC, MIDDLE EAST & AFRICA (APMA)

In an interview with PharmaBoardroom, Iris Zemzoum of Novartis Asia Pacific, Middle East & Africa (APMA) outlines the devastating impact of heart disease such as cardiovascular disease (CVD) as well as Novartis’ multipronged approach to overcoming healthcare disparities across a diverse region that is home to half the world’s population.

​

She elaborated on individual and collective responsibility being key to addressing heart disease and its consequences, and the impact that can be achieved through partnerships with patients, healthcare professionals (HCPs) and the healthcare systems.

​

Iris believes that 80 percent of premature cardiovascular heart disease events can be prevented.

​

Read the article here.